{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:21:26Z","timestamp":1789712486465,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"CSL Vifor"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03402-5","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T07:54:38Z","timestamp":1762934078000},"page":"200-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-analysis and Discussion of Appropriate Methodology"],"prefix":"10.1007","volume":"43","author":[{"given":"Nicolas","family":"Maillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"El Karoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5420-279X","authenticated-orcid":false,"given":"Barnaby","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"2","key":"3402_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"3402_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3402_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ndt\/gfae252","volume":"40","author":"X Shen","year":"2025","unstructured":"Shen X, Chen P, Liu M, Liu L, Shi S, Zhou X, et al. Long-term outcomes of IgA nephropathy in China. Nephrol Dial Transplant. 2025;40(6):1137\u201346.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3402_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091756","volume":"9","author":"T Moriyama","year":"2014","unstructured":"Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS ONE. 2014;9(3):e91756.","journal-title":"PLoS ONE"},{"key":"3402_CR5","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Qualification Process for Drug Development Tools: Guidance for Industry and FDA Staff. https:\/\/www.fda.gov\/media\/133511\/download. Accessed 14 May 2025."},{"key":"3402_CR6","unstructured":"TARPEYO (budesonide) delayed release capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215935s000lbl.pdf. Accessed 14 May 2025."},{"key":"3402_CR7","unstructured":"FILSPARI\u00ae (sparsentan) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216403s003lbl.pdf. Accessed 14 May 2025."},{"key":"3402_CR8","unstructured":"FABHALTA\u00ae (iptacopan) capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218276s001lbl.pdf. Accessed 14 May 2025."},{"key":"3402_CR9","unstructured":"VANRAFIA\u2122 (atrasentan) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219208s000lbl.pdf. Accessed 14 May 2025."},{"key":"3402_CR10","unstructured":"Kinpeygo : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kinpeygo-epar-product-information_en.pdf. Accessed 14 May 2025."},{"key":"3402_CR11","unstructured":"Filspari : EPAR - Product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/filspari-epar-product-information_en.pdf. Accessed 14 May 2025."},{"issue":"12","key":"3402_CR12","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3402_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12874-021-01310-0","volume":"21","author":"M Geissb\u00fchler","year":"2021","unstructured":"Geissb\u00fchler M, Hincapi\u00e9 CA, Aghlmandi S, Zwahlen M, J\u00fcni P, da Costa BR. Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study. BMC Med Res Methodol. 2021;21(1):123.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"3402_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","volume":"68","author":"LA Inker","year":"2016","unstructured":"Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016;68(3):392\u2013401.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"3402_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Inker AL, Floege J, Perkovic V, Boyer-Suavet S, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"3402_CR16","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"},{"issue":"5","key":"3402_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA Nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432\u201342.","journal-title":"JAMA"},{"issue":"8","key":"3402_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1681\/ASN.V1081772","volume":"10","author":"JV Donadio Jr","year":"1999","unstructured":"Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol. 1999;10(8):1772\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3402_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1681\/ASN.V124791","volume":"12","author":"JV Donadio Jr","year":"2001","unstructured":"Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001;12(4):791\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3402_CR20","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Guti\u00e9rrez E, Gonz\u00e1lez E, Morales E, Hern\u00e1ndez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14(6):1578\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3402_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK Li","year":"2006","unstructured":"Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47(5):751\u201360.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3402_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","volume":"41","author":"R Katafuchi","year":"2003","unstructured":"Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, Ando T, Yanase T, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003;41(5):972\u201383.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3402_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"3402_CR24","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694\u2013701.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3402_CR25","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65(5):1842\u20139.","journal-title":"Kidney Int"},{"issue":"10","key":"3402_CR26","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G, Lin J, Rosenstock J, Markowitz G, D\u2019Agati V, Radhakrishnan J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20(10):2139\u201345.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3402_CR27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2010010117","volume":"21","author":"C Pozzi","year":"2010","unstructured":"Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21(10):1783\u201390.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3402_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5301\/jn.5000110","volume":"26","author":"C Pozzi","year":"2013","unstructured":"Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, et al. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol. 2013;26(1):86\u201393.","journal-title":"J Nephrol"},{"issue":"10388","key":"3402_CR29","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584\u201394.","journal-title":"Lancet"},{"issue":"10417","key":"3402_CR30","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390.","journal-title":"Lancet"},{"issue":"2","key":"3402_CR31","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1541-0420.2008.01106.x","volume":"65","author":"MM Joffe","year":"2009","unstructured":"Joffe MM, Greene T. Related causal frameworks for surrogate outcomes. Biometrics. 2009;65(2):530\u20138.","journal-title":"Biometrics"},{"key":"3402_CR32","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: Guidance for Undertaking Reviews in Health Care. York: University of York; 2009. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 14 May 2025."},{"key":"3402_CR33","unstructured":"National Institute of Health and Care Excellence. The guidelines manual. Process and methods (PMG6). https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/developing-review-questions-and-planning-the-systematic-review. Accessed 14 May 2025."},{"issue":"1","key":"3402_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324.","journal-title":"Kidney Int"},{"issue":"2","key":"3402_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"FF Hou","year":"2023","unstructured":"Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254054.","journal-title":"JAMA Netw Open"},{"issue":"10405","key":"3402_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370.","journal-title":"Lancet"},{"issue":"2","key":"3402_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/00031305.2016.1154108","volume":"70","author":"RL Wasserstein","year":"2016","unstructured":"Wasserstein RL, Lazar NA. The ASA statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):29\u2013133.","journal-title":"Am Stat"},{"issue":"4","key":"3402_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","volume":"31","author":"S Greenland","year":"2016","unstructured":"Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337\u201350.","journal-title":"Eur J Epidemiol"},{"issue":"12","key":"3402_CR39","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1016\/j.ekir.2022.09.017","volume":"7","author":"RA Lafayette","year":"2022","unstructured":"Lafayette RA, Reich HN, Stone AM, Barratt J. One-year estimated GFR slope independently predicts clinical benefit in immunoglobulin A nephropathy. Kidney Int Rep. 2022;7(12):2730\u20133.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3402_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003019","volume":"17","author":"JF Tierney","year":"2020","unstructured":"Tierney JF, Fisher DJ, Burdett S, Stewart LA, Parmar MKB. Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study. PLoS Med. 2020;17(1):e1003019.","journal-title":"PLoS Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03402-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:32:15Z","timestamp":1769765535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03402-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicolas Maillard has received consulting and travel fees from CSL Vifor and consulting fees from Alexion. Khalil El Karoui has received consulting and travel fees from CSL Vifor and Novartis and consulting fees from Alexion. Alex Mercer is a consultant to Travere Therapeutics Inc. through contract with JAMCO Pharma Consulting AB. Barnaby Hunt is an employee of Ossian Health Economics and Communications, which received consulting fees from CSL Vifor to support preparation of the analysis. Kevin J Carroll is a director of KJC Statistics Ireland Ltd., which has received consulting fees from Travere Therapeutics Inc and CSL Vifor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}